ClinicalTrials.gg
CompletedNCT06930612Updated Nov 9, 2026

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-1)

A Phase 2 interventional study of CM512 and Placebo in Chronic Rhinosinusitis With Nasal Polyposis, sponsored by Beijing Keymed Biosciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Beijing Keymed Biosciences Co., Ltd. (part of Keymed Biosciences Co.Ltd) · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Rhinosinusitis with a site in China — 18 open to participants now, 25 under way, 7 of them phase 3. Rhinosinusitis · China.

Enrollment
16th of 36
120 · median 117
Started
2025
with 9 others
Phase 2
12 of 40
4 open now
Registered
26th of 40
by date
Lead sponsor
2 of 40
Beijing Keymed Biosciences Co., Ltd.

Among the 40 studies in Rhinosinusitis with a site in China, this one is the 16th largest by enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2025, is one of 12 in phase 2, and was the 26th registered.

Rhinosinusitis

251 studies on the registry are indexed under Rhinosinusitis; 69 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

18 of the 40 studies in Rhinosinusitis with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 33 Rhinosinusitis studies recruiting now, 14 (42%) set no upper age limit and 13 (39%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Rhinosinusitis with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM512, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immunogenicity of CM512 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).

Read the detailed description

The study consists of a Screening Period (up to 4 weeks), Treatment Period (24 weeks for double-blind treatment period) and Safety Follow-up Period (12 weeks).

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyposis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • with chronic rhinosinusitis with nasal polyposis (CRSwNP).
  • Nasal Polyp Score (NPS) of ≥5 with a minimum score of 2 in each nasal cavity.
  • Nasal Congestion Score of 2 or 3 at screening period, and at least 2 at baseline.
  • .

Exclusion criteria

Exclusion Criteria:

  • Not enough washing out period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for Interleukin (IL)-4 receptor alpha subunit antagonists, less than 8 weeks or 5 half-lives for biologic therapy/systemic , less than 6 months for sinus surgery (including polypectomy).With malignant or benign tumor of nasal cavity.
  • Vaccination with within 30 days before randomization or during the planned study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    CM512 Dose 1

    Biological: CM512

  • Experimental
    CM512 Dose 2

    Biological: CM512

  • Experimental
    CM512 Dose 3

    Biological: CM512

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • BiologicalCM512

    Administered subcutaneous injection

  • DrugPlacebo

    Administered subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Nasal Polyps Score (NPS)

    Change from baseline in the Nasal Polyps Score (NPS) at week 24. NPS score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: at week 24

Secondary outcomes

  1. Change from baseline in NPS at other evaluation visits

    Time frame: baseline up to week 36

  2. Change from baseline in Nasal Congestion Score (NCS) at each evaluation visit

    Time frame: baseline up to week 36

  3. Proportion of subjects achieving an improvement in NPS from baseline of ≥ 1 point and ≥ 2 points at each evaluation visit

    Time frame: baseline up to week 36

  4. Change from baseline in Total Symptom Score (TSS) at each evaluation visit

    Time frame: baseline up to week 36

  5. Change from baseline in loss-of-smell (LoS) score at each evaluation visit

    Time frame: baseline up to week 36

  6. Change from baseline in Lund-Mackay (LMK) score evaluated by sinus computed tomography (CT) at each evaluation visit

    Time frame: baseline up to week 36

  7. Change from baseline in 22-item Sino-nasal Outcome Test (SNOT-22) score at each evaluation visit

    Time frame: baseline up to week 36

  8. Incidence of adverse events (AEs)

    Time frame: baseline up to week 36

  9. Physical examination

    Time frame: baseline up to week 36

  10. Vital signs

    Time frame: baseline up to week 36

  11. 12-lead electrocardiogram (ECG)

    Time frame: baseline up to week 36

  12. clinical laboratory tests

    Time frame: baseline up to week 36

  13. Plasma concentrations of CM512

    Time frame: baseline up to week 36

  14. Change from baseline and percent change from baseline in serum total immunoglobulin E (IgE) level at each evaluation visit

    Time frame: baseline up to week 36

  15. Change from baseline and percent change from baseline in peripheral blood eosinophil (EOS) level at each evaluation visit

    Time frame: baseline up to week 36

  16. Change from baseline and percent change from baseline in serum interleukin-5 (IL-5) level at each evaluation visit

    Time frame: baseline up to week 36

  17. Change from baseline and percent change from baseline in serum interleukin-13 (IL-13) level at each evaluation visit

    Time frame: baseline up to week 36

  18. Change from baseline and percent change from baseline in serum thymic stromal lymphopoietin (TSLP) level at each evaluation visit

    Time frame: baseline up to week 36

  19. Change from baseline and percent change from baseline in serum thymus and activation-regulated chemokine (TARC) level at each evaluation visit

    Time frame: baseline up to week 36

  20. Change from baseline and percent change from baseline in serum eotaxin-3 level at each evaluation visit

    Time frame: baseline up to week 36

  21. Change from baseline and percent change from baseline in serum chemokine 13 (CCL13) level at each evaluation visit

    Time frame: baseline up to week 36

  22. Change from baseline and percent change from baseline in serum chemokine 22 (CCL22) level at each evaluation visit

    Time frame: baseline up to week 36

  23. Change from baseline and percent change from baseline in serum periostin level at each evaluation visit

    Time frame: baseline up to week 36

  24. Change from baseline and percent change from baseline in EOS levels in nasal polyp biopsy tissue

    Time frame: baseline up to week 24

  25. Incidence of Anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs)

    Time frame: baseline up to week 36

Other outcomes

  1. Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) score at each evaluation visit in subjects coexisting asthma

    Time frame: baseline up to week 36

  2. Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at each evaluation visit in subjects coexisting asthma

    Time frame: baseline up to week 36

07

Study locations

1 site
  • Beijing Tong-Ren hospital
    Beijing, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Apr 2026, 10 months.

Of 16 phase 2 interventional studies under Rhinosinusitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 10 months is below that.

Start moved once since we started tracking on Sep 25, 2026: May 2025 → Jun 2025, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 16, 2025
StartActual
Jun 12, 2025was May 2025
Primary completionActual
Apr 20, 2026
CompletionActual
Jul 10, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 16, 2025→Jun 12, 2025
Nov 9, 2026
Secondary outcomes
22 edited, 2 added
What changed in the outcomes
  • EditedChange from baseline in NPS at other evaluation visitsTime frame: baseline up to week 36
  • EditedChange from baseline in Nasal Congestion Score (NCS) at each evaluation visitTime frame: baseline up to week 36
  • EditedProportion of participantssubjects achieving an improvement in NPS from baseline of ≥ 1 point and ≥ 2 points at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline in Total Symptom Score (TSS) at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline in Loss loss-of Smell-smell (LoS) score at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline in Lund-Mackay (LMK) score evaluated by sinus computed tomography (CT) at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline in 22-item Sino-nasal Outcome Test (SNOT-22) score at each evaluation visitTime frame: baseline up to week 36
  • EditedIncidence of treatment-emergent adverse events (TEAEsAEs)Time frame: baseline up to week 36
  • EditedphysicalPhysical examinationTime frame: baseline up to week 36
  • EditedvitalVital signsTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum total immunoglobulin E (IgE) level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in peripheral blood eosinophil (EOS) level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum interleukin-5 (IL-5) level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum interleukin-13 (IL-13) level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum thymic stromal lymphopoietin (TSLP) level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum thymus and activation-regulated chemokine (TARC) level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum eotaxin-3 level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum chemokine 13 (CCL13) level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum chemokine 22 (CCL22) level at each evaluation visitTime frame: baseline up to week 36
  • EditedChange from baseline and percent change from baseline in serum periostin level at each evaluation visit.Time frame: baseline up to week 36
  • EditedIncidence of Anti-drug antibodies (ADAADAs) and neutralizing antibodies (Nabs)Time frame: baseline up to week 36
  • ChangedBefore Concentration of CM512 in serumNow Plasma concentrations of CM512Time frame: baseline up to week 36
  • Addedother outcomeChange from baseline in Asthma Control Questionnaire-6 (ACQ-6) score at each evaluation visit in subjects coexisting asthmaTime frame: baseline up to week 36
  • Addedother outcomeChange from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at each evaluation visit in subjects coexisting asthmaTime frame: baseline up to week 36
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date May 16, 2025→Jun 12, 2025
    Secondary outcomes 22 edited, 2 added
    What changed in the outcomes
    • EditedChange from baseline in NPS at other evaluation visitsTime frame: baseline up to week 36
    • EditedChange from baseline in Nasal Congestion Score (NCS) at each evaluation visitTime frame: baseline up to week 36
    • EditedProportion of participantssubjects achieving an improvement in NPS from baseline of ≥ 1 point and ≥ 2 points at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline in Total Symptom Score (TSS) at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline in Loss loss-of Smell-smell (LoS) score at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline in Lund-Mackay (LMK) score evaluated by sinus computed tomography (CT) at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline in 22-item Sino-nasal Outcome Test (SNOT-22) score at each evaluation visitTime frame: baseline up to week 36
    • EditedIncidence of treatment-emergent adverse events (TEAEsAEs)Time frame: baseline up to week 36
    • EditedphysicalPhysical examinationTime frame: baseline up to week 36
    • EditedvitalVital signsTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum total immunoglobulin E (IgE) level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in peripheral blood eosinophil (EOS) level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum interleukin-5 (IL-5) level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum interleukin-13 (IL-13) level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum thymic stromal lymphopoietin (TSLP) level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum thymus and activation-regulated chemokine (TARC) level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum eotaxin-3 level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum chemokine 13 (CCL13) level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum chemokine 22 (CCL22) level at each evaluation visitTime frame: baseline up to week 36
    • EditedChange from baseline and percent change from baseline in serum periostin level at each evaluation visit.Time frame: baseline up to week 36
    • EditedIncidence of Anti-drug antibodies (ADAADAs) and neutralizing antibodies (Nabs)Time frame: baseline up to week 36
    • ChangedBefore Concentration of CM512 in serumNow Plasma concentrations of CM512Time frame: baseline up to week 36
    • Addedother outcomeChange from baseline in Asthma Control Questionnaire-6 (ACQ-6) score at each evaluation visit in subjects coexisting asthmaTime frame: baseline up to week 36
    • Addedother outcomeChange from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at each evaluation visit in subjects coexisting asthmaTime frame: baseline up to week 36
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06930612
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
Jun 12, 2025
Primary completion
Apr 20, 2026
Completion
Jul 10, 2026
Last update
Nov 9, 2026

Study contacts

Luo Zhang
principal investigator · Beijing Tong-Ren hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CM512

Start the discussion